Biomedical Sciences Graduate Program | University of California, San Francisco

Warner Greene, MD, PhD
Molecular Analysis of HIV Pathogenesis

Selected Publications | Complete Publications

phone	(415) 734-4805
email	wgreene@gladstone.ucsf.edu
additional websites	Gladstone Institute of Virology & Immunology Lab website AIDS Research Institute
secondary research affiliation	Immunology

My laboratory focuses on the pathogenic interplay of the HIV-1 and HTLV-I human retroviruses with cells of the immune system and the diseases that may result, AIDS and the Adult T-cell Leukemia (ATL), respectively. Our current studies are exploring the molecular basis for HIV latency and the biology of innate antiviral factors like APOBEC3G whose actions are antagonized by the HIV Vif gene product. Additionally, we are employing a new virion-based assay to study HIV and HTLV-1 Env-mediated fusion to biologically relevant target cells including CD4 T-cells and dendritic cells and investigating the molecular underpinnings of HIV transmission in the female genital tract.

Selected Publications

Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC. HIV-1 Nef inhibits ASK1-dependent death signaling providing a potential mechanism for protecting the infected host cell. Nature 410:834-838, 2001.

de Noronha CMC, Sherman MP, Lin HW, Cavrois MV, Moir RD, Goldman RD, Greene WC. Dynamic disruptions in nuclear envelope architecture and integrity induced by HIV-1 Vpr. Science 294:1105-1108, 2001.

Chen LF, Fischle W, Verdin E, Greene WC. Duration of nuclear NF-kB action is regulated by reversible acetylation. Science 293:1653-1657, 2001.

Greene WC, Peterlin BM. Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat. Med. 8:673-680, 2002.

Chen LF, Mu Y, Greene WC. Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kB. EMBO J. 21:6539-6548, 2002.

Stopak K, de Noronha C, Yonemoto W, Greene WC. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Mol. Cell 12:591-601, 2003.

Greene WC. The brightening future of HIV therapeutics. Nat. Immunol. 5:867-871, 2004.

Chiu Y-L, Soros VB, Kreisberg JF, Stopak K, Yonemoto W, Greene WC. Cellular APOBEC3G restricts HIV-1 infection in resting CD4 T cells. Nature 435:108-114, 2005.

Williams SA, Chen LF, Kwon H, Ruiz-Jarabo CM, Verdin E, Greene WC. NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25:139-49, 2006

Cavrois M, Neidleman J, Kreisberg JF, Greene WC. In Vitro Derived Dendritic Cells Trans -infect CD4 T Cells Primarily with Surface-bound HIV-1 Virions. PLoS Path. 3:e4, 2007.

Soros VB, Yonemoto W, Greene WC. Newly synthesized APOBEC3G is incorporated into HIV virions, inhibited by HIV RNA, and subsequently activated by RNase H. PLoS Path. e:315, 2007

information last updated May 2007